Zandelisib Plus Rituximab Under Study in Indolent Non-Hodgkin Lymphoma
August 13th 2021Zandelisib plus rituximab is being evaluated as a potentially chemotherapy-free treatment strategy vs standard chemoimmunotherapy in patients with indolent non-Hodgkin lymphoma in first relapse in the ongoing, phase 3 COASTAL trial.